Combination Therapy for Pediatric Asthma Patients

Trial Objective

Combination Therapy for Pediatric Asthma PatientsOur researchers are trying to determine if a combination of fluticasone furoate (FF) and vilanterol (VI) is more effective than FF alone in improving lung function and symptoms such as coughing, wheezing, chest tightness and breathlessness in pediatric asthma patients.

FF (which is approved for treatment of asthma) is typically used to treat asthma in adults. This study is adding the use of VI (which is not currently approved for the treatment of asthma). The study also will determine the safety of the combination of FF and VI. Some participants will receive FF and VI, some others will receive FF alone. There is no placebo for this study.

Enrollment

New enrollment for this trial is temporarily paused

Who Can Participate

Children and teens ages 5 to 17 who have uncontrolled asthma and are receiving stable asthma therapy.

Age: 5-17    Gender: Any Gender


Estimated Time Commitment

7 visits up to 29 weeks

(1) a four-week period during when participants will receive a study medication called Fluticasone Propionate (FP), (2) a 24-week treatment period when participants will not know if they are receiving the study medication.



Payment & Reimbursement  

Payment: Provided

Travel Reimbursement: Available

Trial Contact

For more information, contact:

Michael White

Michael White
303.398.1470

D Sundstrom

Dee Sundstrom
303.398.1470

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors

GlaxoSmithKline (GSK)

Principal Investigators


Request More Information

After limiting clinical research activity due to safety concerns about COVID-19, we are now restarting clinical research in stages. If you are interested in any of the clinical trials posted on our website, please request trial information. We will respond and share the timing for enrollment resuming. Learn More


*
*
*
*